IQVIA

780 articles about IQVIA

• Leslie Wims Morris Joins IQVIA Board of Directors

  1/24/2022

  IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, announced the appointment of Leslie Wims Morris to its board of directors, effective today.

• ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration

  12/6/2021

  ASLAN Pharmaceuticals today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials.

• IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Services Unit

  12/2/2021

  IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, is launching new Research Nursing and Phlebotomy services.

• IQVIA Recognized as a Leader in BPO Solutions for Pharmaceutical Sales and Marketing

  12/1/2021

  IQVIA recognized in IDC MarketScape™ for its data and analytics capabilities and growing suite of software platforms.

• IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance

  10/21/2021

  IQVIA Holdings Inc. today reported financial results for the quarter ended September 30, 2021.

• IQVIA to Announce Third-Quarter 2021 Results on October 21, 2021

  10/12/2021

  IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2021 financial results before the market opens on Thursday, October 21, 2021.

• IQVIA Announces Opening of New Q2 Solutions Innovation Laboratories in North Carolina, Creating New Jobs and Expanded Capabilities

  10/6/2021

  IQVIA Announces Opening of New Q 2 Solutions Innovation Laboratories in North Carolina, Creating New Jobs and Expanded Capabilities

• IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment

  9/13/2021

  IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment

• IQVIA Collaborates with HealthCore to Advance Clinical Research Using Real-World Data

  9/8/2021

  IQVIA™ (NYSE: IQV) announces its strategic collaboration with HealthCore, Inc. to advance real world evidence (RWE) studies with increased quality and efficiency.

• IQVIA to Announce Second-Quarter 2021 Results on July 27, 2021

  7/13/2021

  IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its second-quarter 2021 financial results before the market opens on Tuesday, July 27, 2021.

• IQVIA Launches the Clinical Data Analytics Suite (CDAS) to Enable Smarter, Faster Clinical Trials

  6/24/2021

  IQVIA™ (NYSE: IQV) today introduced Clinical Data Analytics Suite (CDAS) , a new SaaS-based clinical data analytics platform that combines structured and unstructured data from clinical trials into a single, standardized setting for easier access and use.

• IQVIA CFO, Ron Bruehlman, to Speak at the William Blair Growth Stock Conference on June 2, 2021

  5/20/2021

  IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will participate in a virtual fireside chat at the William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 10:20 a.m. EDT.

• Pharma R&D Activity Surges Even Without COVID-19, Says Report from the IQVIA Institute for Human Data Science

  5/19/2021

  Despite significant disruption and reprioritization of clinical trial activity during 2020 due to COVID-19, R&D activity levels remained at historically high levels, driven by new funding and strategic transactions, especially within oncology, according to a new research report Global Trends in R&D: Overview Through 2020 released by the IQVIA™ Institute for Human Data Science.

• U.S. District Court Issues Favorable Decision for IQVIA Against Veeva

  5/10/2021

  IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the U.S. District Court of New Jersey issued a favorable decision in its litigation with Veeva Systems, Inc. (NYSE:VEEV).

• IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug

  5/3/2021

  IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2, 2021.

• Global Medicine Spending to Reach $1.6 Trillion in 2025 Excluding Spending on COVID-19 Vaccines, According to IQVIA Institute for Human Data Science Study

  4/29/2021

  The two leading global therapy areas — oncology and immunology — are forecast to grow 9-12% CAGR through 2025, lifted by significant increases in new treatments and medicine use

• IQVIA Announces Connected Intelligence™

  4/28/2021

  IQVIA (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced Connected Intelligence™, its innovative approach to enabling life sciences customers to discover powerful new insights, drive smarter decision-making, and get treatments to patients faster.

• Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial

  4/6/2021

   Moleculin Biotech, Inc., today announced the engagement of IQVIA Biotech, a contract research organization (CRO) to manage the Company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.

• IQVIA Acquires Remaining Interest in Q2 Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance

  4/1/2021

  IQVIA Acquires Remaining Interest in Q 2 Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance  

• IQVIA Virtual Trial Solutions Used in More than 60 Trials

  3/9/2021

  IQVIA™ announced that more than 60 trials spanning over 40 countries utilize its innovative decentralized clinical trial solutions as part of their respective registration trials.